Monti J M, Alterwain P, Monti D
Department of Pharmacology and Therapeutics, School of Medicine, Clinics Hospital, Montevideo, Uruguay.
J Affect Disord. 1990 Nov;20(3):201-8. doi: 10.1016/0165-0327(90)90145-x.
The effect of moclobemide, a short-acting, reversible, preferential type-A MAO inhibitor (300 mg daily in three divided doses), on the sleep of eight depressed patients was assessed by polysomnographic recordings in a 4-week therapeutic trial. Six patients showed an improvement greater than 50% on the Hamilton Depression Rating Scale. Compared to placebo, patients receiving moclobemide showed improved sleep continuity as judged by the decrease in wake time after sleep onset and total wake time, particularly during the intermediate and late stages of drug administration. Total sleep time increase was comprised of larger amounts of stage 2 NREM sleep. REM sleep latency was significantly increased and REM sleep % decreased during the drug administration period. However, in contrast to the older, non-selective and selective MAOIs, moclobemide had a mild REM sleep suppressant effect.
在一项为期4周的治疗试验中，通过多导睡眠图记录评估了短效、可逆、选择性A型单胺氧化酶抑制剂吗氯贝胺（每日300毫克，分三次服用）对8名抑郁症患者睡眠的影响。6名患者在汉密尔顿抑郁量表上的改善超过50%。与安慰剂相比，服用吗氯贝胺的患者睡眠连续性得到改善，这可通过睡眠开始后清醒时间和总清醒时间的减少来判断，尤其是在药物治疗的中期和后期。总睡眠时间的增加包括更多的2期非快速眼动睡眠。在药物治疗期间，快速眼动睡眠潜伏期显著延长，快速眼动睡眠百分比下降。然而，与较老的非选择性和选择性单胺氧化酶抑制剂不同，吗氯贝胺对快速眼动睡眠有轻度抑制作用。
